Fierce Pharma July 11, 2024
It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look to be letting up anytime soon. But, according to a new report from Evaluate, obesity products are set to take over many familiar stalwarts on the world’s top-selling drugs list by the end of the decade.
If last year marked the industry’s “age of uncertainty,” this one is “pharma’s growth boost,” according to Evaluate’s 2024 world preview report. 2023’s report detailed key assumptions, such as the U.S. market’s profitability and the growth that big M&A deals offer, in flux. Now, more “predicable realities” have entered the picture and seem to be here to stay.
Reflecting a new shift, oncology...
Today's Sponsors
Today's Sponsor